CEO Michel Vanbrabant presented to an audience of institutional and strategic investors at the Innovation Summit Dublin on 13-15 April.
According to Vanbrabant,
Data from ongoing clinical trials showcase how iSTAR Medical’s MINIject is on a trajectory to become a best-in class Minimally Invasive Glaucoma Surgery (MIGS) device.
The promising data on MINIject achieved to date are setting the scene for an ambitious 2021 roadmap for iSTAR Medical. Commercial launch in Europe and expansion of the company’s clinical trial program to the US are anticipated.
In glaucoma treatment, MIGS devices are the fastest growing market segment. Out of all MIGS devices, MINIject combines remarkable efficacy results, including medication reduction, with an excellent safety profile, including extremely low reintervention rates. Glaucoma is the second leading cause of blindness, affecting over 100 million patients worldwide.
Now in its 8th-year, Innovation Summit Dublin 2021 is a leading medical technology investment forum in Europe, bringing together more than 500 leading experts, innovators, and key decision-makers to discuss the ever-evolving global medical device community.
